The efficacy of the first in class anti ASCT2 antibody conjugated with a pyrrolobenzodiazepine dimer (MEDI7247) was tested in a phase I trial (NCT03106428) for R/R AML, diffuse large B cell lymphoma, and multiple myeloma. This evidence concerns the gene SLC1A5 and acute myeloid leukemia.